Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV-specific DC-CIK cell therapy
- Development stage
- Unknown
- Lead developer
- Shenzhen Second People’s Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
HPV-specific DC-CIK cell therapy is an autologous cellular immunotherapy being investigated for the treatment of refractory condyloma acuminatum (genital warts) caused by Human Papillomavirus (HPV). The therapy involves the generation of dendritic cells (DCs) pulsed with HPV-specific antigens, such as E6 and E7 proteins, to prime and activate cytokine-induced killer (CIK) cells. CIK cells are a heterogeneous population of T lymphocytes (typically CD3+CD56+) with potent non-MHC-restricted cytolytic activity. By combining the antigen-presenting capabilities of DCs with the cytotoxic power of CIK cells, the therapy aims to specifically target and eliminate HPV-infected cells. In clinical studies, it is often evaluated in combination with interferon-α to enhance the antiviral immune response and reduce recurrence rates in patients who have failed conventional treatments.
- Other names
- HPV-specific dendritic cell-cytokine-induced killer cell therapyHPV-DC-CIK therapyHPV-specific DC-CIK
02
Targets
Human papillomavirus E7 oncoprotein-derived peptide–Human leukocyte antigen class I complexMICB (Major histocompatibility complex class i-related protein B)Human papillomavirus E6 peptide–Human leukocyte antigen class I complex
Beyond the preview
Go deeper on HPV-specific DC-CIK cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPV-specific DC-CIK cell therapy.